Regulatory disclosure

Medical Supervision & State Licensure Disclosure

All clinical care described as “doctor-guided,” “medically supervised,” or “clinician-led” on this site is overseen by the licensed physicians and pharmacist named below. Treatment is available only to patients physically located in a state where the supervising clinician holds an active, unrestricted license.

Clinical leadership team

Levette Owusu-Ansah, PharmDPharmD
Board-Certified Pharmacist
Board-certified pharmacist with 27 years of experience in acute and community pharmacy.
States of licensure / practice
All 50 states (pharmacy services delivered under applicable state pharmacy rules and oversight agreements).
Dr. HindsMD, ABOM
Medical Director
Certified by the American Board of Obesity Medicine (ABOM), SSRP certified in cellular, peptide, and functional medicine, certified in Bioidentical Hormone Replacement Therapy (BHRT), and a Fellow of the American Academy of Anti-Aging Medicine.
States of licensure / practice
Licensed in all 50 states (telehealth oversight).
Dr. ButteMD
Internal Medicine Physician and Clinical Advisor
Internal medicine physician and clinical advisor, leading protocols and education for GLP-1s, peptides, and labs, with a background in longevity clinics and telehealth.
States of licensure / practice
Licensed in all 50 states (telehealth oversight).
Dr. MorseMD
Physician — OB-GYN and Menopause
Physician specializing in OB-GYN and menopause, leading hormone therapy protocols and education, trained at Harvard Medical School, Mayo Clinic, and Johns Hopkins.
States of licensure / practice
Licensed in all 50 states (telehealth oversight).

Extended clinical network

Our leadership team is supported by a broader network of board-certified physicians, nurse practitioners, physician assistants, and pharmacists licensed across all 50 states. Every prescribing or treating clinician is licensed in the state where the patient is located at the time of care, and all prescribing, lab review, and treatment decisions are performed under written oversight agreements with the Medical Director.

License numbers and states

All 50 statesActive
Individual state license numbers available upon request
Issuing board: State medical boards of the patient's location of care

License status may be independently verified through the issuing state medical board. Services are not offered to patients located outside the states where the treating clinician is licensed.

Scope of supervision

Clinical protocols, prescribing decisions, medication review, and treatment plans are reviewed and approved by the supervising clinicians. Where care is delivered by an advanced practice clinician, that clinician practices under a written collaborative or supervisory agreement consistent with the requirements of the patient's state.

Telehealth is not appropriate for emergencies. If you are experiencing a medical emergency, call 911 or go to the nearest emergency department.

Questions or complaints

Patients may contact the practice to request information about the supervising clinicians' credentials, or file a complaint with the state medical board or pharmacy board of the state where care was received.

NAD+ and longevity claims: evidence and limitations

Where our materials reference NAD+, cellular repair, or healthy aging, those statements describe findings from published preclinical and early clinical research — not proven outcomes for any individual patient. NAD+ is a coenzyme required for DNA-repair enzymes (PARPs) and sirtuins, and its tissue levels decline with age. Human trials of NAD+ precursors have consistently shown that oral supplementation raises blood NAD+ levels and is well tolerated, but clinical benefit endpoints such as longevity, reversal of aging, or DNA-repair capacity in humans have not been established.

We do not claim that NAD+ therapy repairs DNA, extends lifespan, or replaces surgical or medical treatment. Any protocol is provided as part of clinician-supervised care after individual evaluation.

Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141.
Review of how NAD+ supports sirtuin and PARP-dependent DNA repair, and how NAD+ availability declines with age.
View source
Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547.
Summarizes animal evidence for NAD+ precursors and notes that human outcome data remain limited.
View source
Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.
Randomized placebo-controlled trial showing NAD+ elevation and good tolerability, without proven anti-aging outcomes.
View source
Elhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome. Cell Rep. 2019;28(7):1717-1728.
Demonstrates measurable NAD+ metabolome changes in older adults, with no significant change in muscle function endpoints.
View source

These statements have not been evaluated by the FDA. NAD+ and related products are not intended to diagnose, treat, cure, or prevent any disease.

Specific state license numbers must be verified and replaced with the clinician's actual license numbers before publishing.